ERK1/2 inhibitor ERAS-007

{
  "id": "MLC-T-ONC-013416",
  "term": "ERK1/2 inhibitor ERAS-007",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.",
  "synonyms": [
    "ERK inhibitor ASN-007",
    "ERK1/2 inhibitor ASN-007",
    "ERK inhibitor ERAS-007"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/erk1-2-inhibitor-eras-007/"
}